Edition:
India

People: Enanta Pharmaceuticals Inc (ENTA.OQ)

ENTA.OQ on NASDAQ Stock Exchange Global Select Market

67.97USD
13 Sep 2019
Change (% chg)

$-1.43 (-2.06%)
Prev Close
$69.40
Open
$69.67
Day's High
$69.98
Day's Low
$67.93
Volume
63,051
Avg. Vol
74,050
52-wk High
$106.23
52-wk Low
$64.05

Vance, Terry 

Mr. Terry C. Vance is Independent Director of the Company. Since June 2013, Mr. Vance has been Chief Business Officer of BioMotiv, LLC, a drug development company affiliated with The Harrington Project. Until January 2018, Mr. Vance was a Managing Member of EGS Healthcare, a late-stage venture capital fund that he co-founded in 2000. Before starting EGS Healthcare, Mr. Vance was a founding partner in Eagle Advisors, which provided strategic advice to emerging biotechnology companies. Prior to Eagle, Mr. Vance was an investment banker, first with Salomon Brothers and then with Goldman Sachs, where he was a vice president in the Capital Markets Division. Mr. Vance received an AB from Princeton University and an MBA from Stanford University.

Basic Compensation

Total Annual Compensation, USD 67,500
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 306,690
Fiscal Year Total, USD 374,190

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Bruce Carter

394,190

Jay Luly

4,508,740

Paul Mellett

1,421,280

Yat Sun Or

1,524,000

Nathaniel Gardiner

1,376,110

Nathalie Adda

1,514,080
As Of  30 Sep 2018